Literature DB >> 29727073

Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.

C Sophia Albott1,2,3, Kelvin O Lim2,4, Miriam K Forbes2, Christopher Erbes3, Susanna J Tye5, John G Grabowski2, Paul Thuras3, Tegan M Batres-Y-Carr2, Joseph Wels6, Paulo R Shiroma2,3.   

Abstract

OBJECTIVE: The present study examined the efficacy, safety, and durability of repeated ketamine infusions for the treatment of comorbid posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) in a sample of veterans.
METHODS: Individuals with comorbid DSM-5-defined PTSD and DSM-IV-defined major depressive disorder (N = 15) received 6 intravenous ketamine infusions (0.5 mg/kg) on a Monday-Wednesday-Friday schedule over a 12-day period from May 2015 to June 2016. Data from outcome measures were collected before and 24 hours after each infusion and weekly for 8 weeks following the final infusion.
RESULTS: Continuous measures of symptom change were significant for both disorders and were associated with large effect sizes (mean decrease in PTSD Checklist for DSM-5 score = 33.3 points [95% CI, 23.0-43.5 points], P < .0005, sample size-adjusted Cohen d [d'] = 2.17; mean decrease in Montgomery-Asberg Depression Rating Scale score = 26.6 points [95% CI, 23.0-30.2 points], P < .0005, d' = 4.64). The remission rate for PTSD was 80.0%, and the response rate for TRD was 93.3%. Participants in remission from PTSD after the infusion series (n = 12) had a median time to relapse of 41 days. Similarly, participants whose depression symptoms responded to the infusion series (n = 14) had a median time to relapse of 20 days. Repeated ketamine infusions were associated with transient increases in dissociative symptoms. No participant reported worsening of PTSD symptoms over the study duration.
CONCLUSIONS: This study, the first open-label study of repeated ketamine infusions in a comorbid population, found rapid and sustained improvement in PTSD and depression symptoms. This report suggests that repeated ketamine treatments are safe and may represent an efficacious treatment for individuals with comorbid PTSD and TRD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02577250. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29727073     DOI: 10.4088/JCP.17m11634

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  22 in total

Review 1.  Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.

Authors:  Ashley A Conley; Amber E Q Norwood; Thomas C Hatvany; James D Griffith; Kathryn E Barber
Journal:  Psychopharmacology (Berl)       Date:  2021-03-31       Impact factor: 4.530

Review 2.  The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

Authors:  Chadi G Abdallah; Gerard Sanacora; Ronald S Duman; John H Krystal
Journal:  Pharmacol Ther       Date:  2018-05-25       Impact factor: 12.310

Review 3.  Anesthesia and the neurobiology of fear and posttraumatic stress disorder.

Authors:  Keith M Vogt; Kane O Pryor
Journal:  Curr Opin Anaesthesiol       Date:  2022-08-19       Impact factor: 2.733

Review 4.  Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon.

Authors:  Kawther N Elsouri; Sahand Kalhori; Diego Colunge; Grant Grabarczyk; George Hanna; Cassidy Carrasco; Andy Aleman Espino; Andres Francisco; Bradley Borosky; Bassem Bekheit; Maha Ighanifard; Andrea A Astudillo; Michelle Demory Beckler
Journal:  Cureus       Date:  2022-05-23

5.  Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series.

Authors:  Hewa Artin; Sean Bentley; Eamonn Mehaffey; Fred X Liu; Kevin Sojourner; Andrew W Bismark; David Printz; Ellen E Lee; Brian Martis; Sharon De Peralta; Dewleen G Baker; Jyoti Mishra; Dhakshin Ramanathan
Journal:  EClinicalMedicine       Date:  2022-05-06

Review 6.  Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.

Authors:  Michael D Kritzer; Nicholas A Mischel; Jonathan R Young; Christopher S Lai; Prakash S Masand; Steven T Szabo; Sanjay J Mathew
Journal:  Ann Clin Psychiatry       Date:  2022-02       Impact factor: 2.691

7.  Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.

Authors:  Patricia T Spangler; James C West; Catherine L Dempsey; Kyle Possemato; Danielle Bartolanzo; Pablo Aliaga; Carlos Zarate; Meena Vythilingam; David M Benedek
Journal:  J Clin Psychiatry       Date:  2020-10-27       Impact factor: 4.384

8.  Predicting and Managing Treatment Non-Response in Posttraumatic Stress Disorder.

Authors:  Gregory A Fonzo; Vecheslav Federchenco; Alba Lara
Journal:  Curr Treat Options Psychiatry       Date:  2020-03-23

9.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

10.  Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial.

Authors:  Nithya Ramakrishnan; Marijn Lijffijt; Charles E Green; Nicholas L Balderston; Nicholas Murphy; Christian Grillon; Tabish Iqbal; Brittany Vo-Le; Brittany O'Brien; James W Murrough; Alan C Swann; Sanjay J Mathew
Journal:  Depress Anxiety       Date:  2021-07-12       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.